Eli Lilly is strategically pivoting its drug development portfolio, notably axing midstage pain candidates and introducing new early-phase assets following recent clinical trial results. The company discontinued mazisotine, a non-opioid pain candidate, after phase 2 trials in diabetic peripheral neuropathic pain showed insufficient progress. Additionally, Lilly ended programs targeting psoriasis and metabolic liver disease. Despite these setbacks, Lilly's recent oral obesity pill, orforglipron, demonstrated 11.2% weight loss over 72 weeks — falling short of injectable competitors like Wegovy and Zepbound. Nevertheless, Eli Lilly’s overall revenues increased by $1.1 billion in Q2 2025. These developments reflect a dynamic recalibration aimed at strengthening Lilly’s pipeline and addressing competitive pressures.